The effectiveness of vaccination against long COVID

A rapid evidence briefing
Key messages

- Fifteen studies were identified that reported on the effectiveness of vaccination against long COVID (search up to 12 January 2022): 7 studies examined whether vaccination before infection reduced the symptoms or incidence of long COVID, 7 studies examined whether vaccination in people with long COVID reduced or cleared the symptoms of long COVID, and 1 study examined both.
- Six of the 8 studies assessing the effectiveness of vaccination before COVID-19 infection suggested that vaccinated cases (1 or 2 doses) were less likely to develop symptoms of long COVID following infection, in the short term (4 weeks after infection), medium term (12 to 20 weeks after infection) and long term (6 months after infection). As all 8 studies included only participants who had COVID-19, the effect of vaccination on reduced incidence of COVID-19 is not accounted for. This means these studies do not give a total population estimate for the effectiveness of vaccines to prevent long COVID, but rather underestimate it.
- From 2 studies that measured individual long COVID symptoms, fully vaccinated cases were less likely to have the following symptoms in the medium or long term than unvaccinated cases: fatigue, headache, weakness in arms and legs, persistent muscle pain, hair loss, dizziness, shortness of breath, anosmia, interstitial lung disease, myalgia, and other pain.
- In studies examining the effect of vaccination among people with long COVID, 3 of 4 studies comparing long COVID symptoms before and after vaccination suggested that more cases reported an improvement in symptoms after vaccination, either immediately or over several weeks. There were, however, some cases in all studies who reported a worsening in symptoms after vaccination.
- Three studies of people with long COVID who were unvaccinated when they were initially infected, compared people who were subsequently vaccinated and people who remained unvaccinated. All these studies suggested that people with long-COVID were less likely to report long COVID symptoms shortly after vaccination, and over longer periods, than people with long COVID who were not subsequently vaccinated. One study looked at the timing of vaccination after COVID-19 diagnosis, and suggested that cases who were vaccinated sooner rather than later after diagnosis were much less likely to report symptoms of long COVID than cases who remained unvaccinated.
- In 3 of the 5 studies reporting on symptom changes following vaccination of people with long COVID, there was a higher proportion of people with long COVID who reported unchanged symptoms following vaccination (up to 70%) than people whose symptoms improved or worsened.
- All studies were observational, so the results may be from differences other than vaccination, and there was large heterogeneity between studies in the definition of long COVID.
Background

Long COVID, also known as post acute sequaleae of a SARS-CoV-2 infection and post COVID-19 syndrome, has several definitions, but typically includes having persistent symptoms of COVID-19, usually for weeks but potentially for months or years (1, 2). Symptoms commonly include fatigue, shortness of breath and a persistent cough, although many other symptoms have been reported (3). As of 6 December 2021, 1.3 million people in the UK (2% of the population) reported experiencing long COVID symptoms for more than 4 weeks after the initial infection (4). Vaccination against COVID-19 reduces the risk of symptomatic COVID-19 infection (5), though vaccination may additionally reduce the risk of long COVID if a vaccinated person is infected with COVID-19 (1, 2). While there is no recommendation against vaccination in people with long COVID (6), it is unclear whether vaccination of previously unvaccinated people with long COVID is more likely to improve or worsen long COVID symptoms (7, 8).

The purpose of this rapid evidence briefing is to provide evidence relating to the effectiveness of vaccination against long COVID, both for vaccinations given before infection with COVID-19 (effectiveness against incidence of long COVID), and for vaccinations given after infection with COVID-19 and development of long COVID symptoms (effectiveness for reducing or eliminating symptoms of long COVID).

Methods

A rapid search was undertaken on 12 January 2022 to identify primary studies related to the effectiveness of vaccination against long COVID. We searched a number of specialist COVID-19 review repositories and ran a broad search using Medline, Embase, NLM COVID portfolio (for preprints), WHO COVID Database and Google. As this work was conducted at pace, data was extracted directly into a narrative summary. The quality criteria checklist (QCC) tool was used to rate the quality of included studies as low, medium, or high quality. Full details of the methods are available in Appendix A.

Evidence

Fifteen studies reported on the effectiveness of vaccination against long COVID. Four studies were conducted in the UK (7-10), 4 studies in the US (11-14), 1 study in France (15), 2 studies in India (16, 17), 1 study in Indonesia (18), 1 study in Israel (19), and 2 studies were conducted online with participants from multiple countries (20-22). Seven studies examined whether vaccination before infection reduced the symptoms or incidence of long COVID (9, 11, 12, 16-19), 7 studies examined whether vaccination in people with long COVID reduced or cleared the symptoms of long COVID (7, 8, 10, 14, 15, 20-22), and 1 study examined both (13). Table 1 shows the characteristics of each included study.

Most studies used different definitions of long COVID, as such these definitions are given in the summaries below. In all studies, fully vaccinated is defined as 2 doses of any 2 dose vaccine or 1 dose of a single dose vaccine, and partially vaccinated is defined as a single dose of a 2 dose vaccine. Where the vaccine brand (e.g. Pfizer, AstraZeneca) is available, this is reported.
Vaccination before infection

Note that all 8 studies included in this section only include participants who had COVID-19, so the effect of vaccination to reduce incidence of COVID-19 is not accounted for. This means all studies will likely underestimate the effectiveness of vaccines to prevent long COVID.

A nested case-control study by Antonelli et al (2022, rated as medium quality) examined whether vaccination for COVID-19 before infection was associated with long duration symptoms of COVID-19 (≥28 days) in adults who reported testing positive on RT-PCR or LFD for COVID-19 on the COVID symptom study phone app (ZOE) between 8 December 2020 and 4 July 2021 in the UK (9). In total, 6,030 participants reported a positive test at least 14 days after their first vaccination but before their second (partially vaccinated, tested a median of 67 days after vaccination), and 2,370 at least 7 days after their second vaccine (fully vaccinated, tested a median of 44 days after vaccination). The same number of unvaccinated participants who tested positive were matched with those who were partially and fully vaccinated, accounting for date of positive test, healthcare worker status, sex, body mass index, and age.

- Fully vaccinated participants were about half as likely to have symptoms lasting ≥28 days than unvaccinated participants (odds ratio [OR] = 0.51, 95% CI: 0.32 to 0.82, p=0.005), whereas partially vaccinated participants were about as likely to have symptoms lasting ≥28 days than unvaccinated participants (OR = 1.04, 95% CI: 0.86 to 1.25, p=0.69).
- Fully vaccinated younger adults (18 to 59 years) were much less likely to have symptoms lasting ≥28 days than younger unvaccinated adults (OR = 0.21, 95% CI: 0.08 to 0.59, p=0.003).

A retrospective cohort study by Al-Aly et al (2021, preprint, rated as medium quality) examined whether vaccination for COVID-19 before infection was associated with post-acute sequelae of COVID-19 (symptoms of COVID-19 at 6 months) in adults who had a positive test for COVID-19 in the United States Veterans Health Administration electronic health databases between 1 February and 31 August 2021 in the US (12). Vaccinated cases (n=16,035, mean age of 67 years, 71% White race, 91% male) were matched (and weighted) with unvaccinated cases (n=48,536, mean age of 56 years, 71% white, 86% male), accounting for age, race, sex, socioeconomic deprivation, smoking status, health conditions and information, data of test and hospital information. Post-acute sequelae of COVID-19 included cardiovascular disorders, coagulation, fatigue, gastrointestinal disorders, kidney disorders, mental health disorders, metabolic disorders, musculoskeletal disorders, neurologic disorders, and pulmonary disorders.

- Vaccinated cases were less likely to have at least 1 post-acute sequelae of COVID-19 at 6 months compared with unvaccinated cases (hazard ratio [HR] = 0.87, 95% confidence interval [CI]: 0.83 to 0.92).
A retrospective cohort study by Arjun et al (2022, preprint, rated as medium quality) examined whether vaccination for COVID-19 before infection (confirmed with RT-PCR) was associated with self-reported long COVID symptoms (including fatigue, cough, loss of taste and smell and cognitive dysfunction) 4 weeks from the date of diagnosis in adults (≥18 years) who were diagnosed with COVID-19 between April and September 2021 in India (16). In total, 487 participants who tested positive for COVID-19 in a single hospital responded, with a mean age of 39 years, 41% female, and 59% of participants had 2 doses of a COVID-19 vaccine (the majority had Covaxin), 17% had 1 dose, and 25% were unvaccinated. The analysis was adjusted for age, sex, occupation, body mass index, substance use, past COVID-19 infection, comorbidities, number of COVID-19 symptoms and severity of COVID-19 disease.

- Fully vaccinated participants were more likely to have long COVID symptoms 4 weeks from the date of diagnosis than unvaccinated participants (OR = 2.32, 95% CI: 1.17 to 4.58, p=0.01).
- Note that these results are in the opposite direction to all other studies, i.e. that cases who were fully vaccinated had a greater chance of subsequently developing long COVID symptoms, and more analysis is needed to understand why this may be the case.

A retrospective cohort study (POST-COVID) by Herman et al (2022, preprint, rated as medium quality) examined whether vaccination for COVID-19 before infection with COVID-19 (confirmed by RT-PCR, Nucleic Acid Amplification Test [NAAT] or rapid antigen test) was associated with olfactory dysfunction (anosmia or hyposmia) 2 and 4 weeks after the end of infection in cases recruited up to December 2021 in Indonesia (18). Fully vaccinated participants (2 doses, n=221, mean age of 32 years, 50% female) more than 14 days before infection were matched with participants who were not fully vaccinated more than 14 days before infection (including unvaccinated and partially vaccinated cases, n=221, mean age of 32 years, 50% female), accounting for occupation, education, island, type of living area, living companion, age and hypertension status.

- While fully vaccinated participants were less likely to develop olfactory dysfunction after infection than unvaccinated participants (OR = 0.31, 95% CI: 0.10 to 0.94), there was little evidence for an association between full vaccination and olfactory dysfunction 4 weeks after the end of infection (p=0.59).

A cross-sectional study nested in a prospective cohort study by Kuodi et al (2022, preprint, rated as medium quality) examined whether vaccination for COVID-19 before infection was associated with long-term physical, mental, and psychosocial consequences of COVID-19 in adults who tested positive for COVID-19 (RT-PCR) between 15 March 2020 and 15 June 2021 in Israel (19). Study participants (n=951, 294 fully vaccinated [2 doses], 340 partially vaccinated [1 dose], 317 unvaccinated), who tested positive for COVID-19 in 1 of 3 government hospitals, completed a survey between 16 July and 18 November 2021 detailing their COVID-19 test results, vaccination status, number of doses, type of vaccine and date of administration, and symptoms experienced at the time of filling out the survey.
In total, 337 of 951 participants (35%) reported not fully recovering from the initial COVID-19 symptoms at follow-up.

- The study suggested that, compared with unvaccinated participants, participants with 2 or 3 doses of vaccine were 54% to 83% less likely to report 7 of the 10 most commonly reported symptoms (see below).
- For most symptoms, the vaccine effectiveness against symptoms reported at follow-up was highest for older participants (>60 years) and lowest for younger participants (19 to 35 years), with the exceptions of hair loss (highest in 36 to 60 year olds), persistent cough (similar in all age groups) and feeling fully recovered from COVID-19 (highest in 19 to 35 year olds).
- The relative risks (RR) of each symptom, comparing participants who received 2 or 3 doses of vaccine with unvaccinated participants (relative risks <1 indicate that fewer vaccinated compared with unvaccinated participants had the symptom at follow-up) were:
  - Fatigue: RR = 0.36 (95% confidence interval (CI): 0.19 to 0.71, p=0.003)
  - Headache: RR = 0.46 (95% CI: 0.26 to 0.83, p=0.01)
  - Weakness in arms and legs: RR = 0.43 (95% CI: 0.20 to 0.94, p=0.03)
  - Persistent muscle pain: RR = 0.32 (95% CI: 0.11 to 0.88, p=0.03)
  - Loss of concentration: RR = 0.59 (95% CI: 0.17 to 2.06, p=0.41)
  - Hair loss: RR = 0.17 (95% CI: 0.06 to 0.60, p=0.005)
  - Sleeping problems: RR = 0.53 (95% CI: 0.18 to 1.61, p=0.26)
  - Dizziness: RR = 0.26 (95% CI: 0.09 to 1.79, p=0.02)
  - Persistent cough: RR = 0.72 (95% CI: 0.28 to 1.83, p=0.48)
  - Shortness of breath: RR = 0.23 (95% CI: 0.07 to 0.84, p=0.03)
  - Feeling fully recovered from COVID-19: RR = 0.98 (95% CI: 0.80 to 1.21, p=0.86)

A cross-sectional study by Senjam et al (2021, preprint, rated as medium quality) examined whether vaccination for COVID-19 before infection was associated with symptoms of long COVID (symptoms present between 4 and 12 weeks [short-term] or beyond 12 weeks [long-term] after a positive RT-PCR or cartridge based NAAT) in adults (≥18 years) who tested positive for COVID-19 between 1 January and 30 April 2021 in India (17). A total of 773 participants, who tested positive in a single hospital, completed a survey between June and July 2021 (median age of 34 years, 56% male, 33% with short-term long COVID symptoms, 13% with long-term long COVID symptoms, 53% unvaccinated, 25% fully vaccinated [2 doses]). The most commonly reported long COVID symptoms were fatigue, pain in the joints and muscle, hair loss, headache, cough, breathlessness, sleep disorders, sore throat and decrease of smell and taste.

- Fully vaccinated (2 doses) participants were less likely to have long COVID symptoms (not stated if these were short-term, long-term or both) than unvaccinated participants (OR = 0.55, 95% CI: 0.37 to 0.85)
A retrospective cohort study by Simon et al (2021, preprint, rated as high quality) examined whether vaccination for COVID-19 before or after infection was associated with long COVID (COVID-19 symptoms present between 12 and 20 weeks after COVID-19 diagnosis) in cases who were diagnosed with, or tested positive for (NAAT or antigen test), COVID-19 between 1 January 2020 and 31 May 2021 in the US (13). In total, 240,648 cases were included, 220,460 (92%) cases were unvaccinated by 12 weeks after their COVID-19 diagnosis, 2,392 (1.0%) cases received 1 dose of vaccine before their diagnosis, and 17,796 (7.4%) cases received 1 dose of vaccine within 12 weeks of their diagnosis. COVID-19 symptoms included: chest pain, palpitations, altered mental state, anorexia, chills, fatigue, fever, malaise, loss of sense of smell, loss of sense of taste, nasal congestion, sore throat, abdominal pain, diarrhoea, digestive changes, nausea, vomiting, arthralgia, muscle weakness, general weakness, myalgia, headache, cough and dyspnoea.

- Cases who were vaccinated before diagnosis were much less likely to have any symptoms of long COVID between 12 and 20 weeks after diagnosis than cases who were unvaccinated up to 12 weeks after their diagnosis (OR = 0.22, 95% CI: 0.20 to 0.25, p<0.005), and even less likely to have more than 1 symptom of long COVID (OR = 0.11, 95% CI: 0.09 to 0.14, p<0.005)

A matched case-control study by Taquet et al (2021, preprint, rated as high quality) examined whether vaccination for COVID-19 before infection (confirmed diagnosis or positive RT-PCR test) was associated with documented consequences of COVID-19 in people in the 6 months after an infection, with infection occurring between 1 January and 31 August 2021, primarily in the US (11). Data was obtained from TriNetX Analytics, which contains data from 59 healthcare organisations and 81 million patients. In total, 9,479 vaccinated cases (n=2,996 with 1 dose and n=6,957 with 2 doses of any vaccine received at least 14 days before infection during the study) were matched with the same number of unvaccinated cases (who had received an influenza vaccine), accounting for age, sex, ethnicity, obesity, socioeconomic deprivation and specific health conditions, as well as date of infection. The mean age of participants was 57 years, 59% were female, and of those who were vaccinated, 65% had the Pfizer vaccine, 9% the Moderna vaccine, 1.6% the Janssen vaccine, and 24% had an unspecified vaccine. A composite long COVID outcome was defined as having a diagnosis of any of the following symptoms in the 6 months after infection: abdominal symptoms, abnormal bleeding, anxiety/depression, chest/throat pain, cognitive symptoms, fatigue, headache, myalgia and other pain, as well as death (to account for differences in survival between vaccinated and unvaccinated participants).

- The study suggested there was no association between vaccination (comparing participants with 2 doses of vaccine with unvaccinated participants) and the composite long COVID outcome in the 6 months after infection: hazard ratio (HR) = 1.00 (95% CI: 0.95 to 1.06); 64.9% and 65.6% of vaccinated and unvaccinated participants had a long COVID symptom respectively.

- However, participants with 2 doses of vaccine, when compared with unvaccinated participants, were less likely to be diagnosed with:
  - Anosmia: HR = 0.68 (95% CI: 0.55 to 0.84, p=0.0004)
  - Fatigue: HR = 0.86 (95% CI: 0.77 to 0.96, p=0.005)
Hair loss: HR = 0.66 (95% CI: 0.54 to 0.81, p<0.0001)
Interstitial lung disease: HR = 0.74 (95% CI: 0.62 to 0.88, p=0.0006)
Myalgia: HR = 0.70 (95% CI: 0.59 to 0.84, p<0.0001)
Other pain: HR = 0.85 (95% CI: 0.76 to 0.96, p=0.007)

**Vaccination after infection**

A prospective cohort by Arnold et al (2021, preprint, rated as medium quality) examined the effect of vaccination (with Pfizer or AstraZeneca) on long COVID symptoms in previously unvaccinated participants who were hospitalised with COVID-19 in April and May 2020 and either remained unvaccinated or were vaccinated (Pfizer or AstraZeneca) in January or February 2021 in the UK (7). Vaccinated participants (n=44, median age 64 years, 64% male, 82% symptomatic 8 months after infection) were matched with unvaccinated participants (n=22, median age 55 years, 59% male, 82% symptomatic 8 months after infection), accounting for symptomatology and quality of life at 8 months after infection, and all participants were asked about whether they had symptoms, and whether they had improved, stayed the same, or worsened following vaccination.

- At 1 month after vaccination (or a matched time for unvaccinated cases), more vaccinated participants reported their symptoms improved than unvaccinated participants (23.2% versus 15.4%), and fewer vaccinated participants reported their symptoms worsened than unvaccinated participants (25.6% versus 14.3%, p=0.035 for all differences). A similar percentage of vaccinated and unvaccinated participants had unchanged symptoms (71.1% versus 70.3%).

A prospective cohort (the Office of National Statistics COVID-19 infection survey [CIS]) study by Ayoubkhani et al (2021, preprint, rated as high quality) examined the effect of vaccination on long COVID symptoms in previously unvaccinated adults (18 to 69 years) between 3 February and 5 September 2021 in the UK (8). Participants in the CIS were randomly sampled from UK households, and were visited monthly to both provide a swab for RT-PCR testing and to be asked if they would describe themselves as currently experiencing long COVID (in this analysis, symptoms persisting at least 12 weeks from a confirmed or suspected COVID-19 infection that could not be explained by another health condition). All participants had their first vaccine dose by 5 September 2021 (n=28,356), 45.7% after 3 February 2021, and 83.8% had their second vaccine dose by 5 September 2021 (n=23,753). There were 6,729 participants (23.7%) that reported they had long COVID symptoms, including fever, headache, muscle ache, weakness or tiredness, nausea or vomiting, abdominal pain, diarrhoea, loss of appetite, loss of taste, loss of smell, sore throat, cough, shortness of breath, chest pain, palpitations, vertigo or dizziness, worry or anxiety, low mood or not enjoying anything, trouble sleeping, memory loss or confusion, or difficulty concentrating.

- Both the first and second vaccine doses were associated with reduced odds of reporting long COVID symptoms shortly after vaccination:
  - First vaccine dose: OR = 0.87 (95% CI: 0.81 to 0.93, p<0.001)
  - Second vaccine dose: OR = 0.91 (95% CI: 0.86 to 0.97, p=0.003)
The second vaccine dose was also associated with a long-term decrease in the odds of reporting long COVID symptoms (p=0.03).

- The results were similar for activity limiting long COVID (n=4,747 reported activity limiting long COVID):
  - First vaccine dose: OR = 0.88 (95% CI: 0.81 to 0.96, p=0.003)
  - Second vaccine dose: OR = 0.91 (95% CI: 0.84 to 0.98, p=0.01)
  - The second vaccine dose was also associated with a long-term decrease in the odds of reporting long COVID symptoms (p=0.03)

- There was little evidence for differences in results between mRNA and adenovirus vaccine types, and the results suggested that the odds of experiencing most symptoms of long COVID decreased with the first and second doses of vaccine, though these results were relatively imprecise.

A prospective cohort study by Gaber et al (2021, rated as medium quality) asked health care workers in the UK with long COVID whether vaccination between December 2020 and January 2021 changed their long COVID symptoms (10). Of 67 healthcare workers with long COVID receiving the vaccine, 75% had fatigue, 53% had shortness of breath, and 18% had anxiety.

- Several weeks after vaccination, 14 (21%) participants reported an improvement in 1 or more of their symptoms, 8 (12%) participants reported a worsening in symptoms, and 45 (67%) participants reported no change in their symptoms.

An online survey (LongCovidSOS) by Strain et al (2021, preprint, rated as medium quality) asked people in the UK and elsewhere with long COVID (positive RT-PCR or antigen test not required) whether their symptoms improved or worsened following vaccination (21, 22). The survey was completed by 812 respondents (96% above 30 years old, 80% women) in March and April 2021, 41% of participants had a confirmed COVID-19 infection, 50% had the AstraZeneca vaccine, 40% the Pfizer vaccine, 8.6% the Moderna vaccine, 14% had 2 doses of any vaccine, and 40% of participants had at least 30 days between their last vaccine and completing the survey. Long COVID symptoms included fatigue, brain fog, myalgia, shortness of breath, insomnia, chest pain or palpitations, gastrointestinal symptoms, anosmia, autonomic dysfunction, postural orthostatic tachycardia syndrome, persistent cough, fever, rash (including COVID toes) and vascular complications.

- 57% of participants reported an improvement in symptoms after vaccination, 25% of participants reported no change in symptoms, while 19% of participants reported a worsening of symptoms, with Moderna having the most participants report an improvement and least report a deterioration.

- When responses to individual symptoms were grouped together, more participants had all or some of their symptoms improve than worsen:
  - All improved: 11%
  - Some improved: 16%
  - Mixture: 24%
  - No change: 42%
Some got worse: 3.8%
All got worse: 2.9%

An online survey by Scherlinger et al (2022, rated as medium quality) asked French-speaking adults with post-acute sequelae of COVID-19 (PASC, persistent symptoms lasting >4 weeks after probable or confirmed COVID-19 infection and no alternative diagnosis to explain the symptoms) whether their symptoms improved or worsened following vaccination (Pfizer [78%], Moderna [16%], AstraZeneca [4%]) (20). The survey was completed by 567 respondents (median age 44 years, 83% women) in August 2021, 64% of participants had a confirmed COVID-19 infection, 25% had one vaccine dose and 45% had 2 vaccine doses. Symptoms of PASC included fever or chills, fatigue, brain fog, headaches, changing mood or impact on morale, sleeping issues, costal pain, dyspnoea, cough, palpitations, muscle aches, joint pain, paraesthesia or tingling, anosmia or ageusia, diarrhoea or vomiting, spontaneous bruises, and pruritus.

- Of the 380 participants who reported long COVID at the time of vaccination, 117 (31%) reported a global worsening of symptoms (including fever/chills [74%], gastro-intestinal symptoms [70%], paraesthesia [64%] and arthralgia [63%]), whereas 83 (21.8%) reported a global improvement in symptoms (including anosmia [62%] and brain fog [51%]), and 179 (47%) reported no change in symptoms following vaccination.
- The symptoms thought to be affected by vaccination persisted for more than 2 weeks after vaccination in 64% of participants reporting a worsening in symptoms, and in 73% of participants reporting an improvement.
- There was little evidence of differences in results between vaccine types (p=0.60)

A retrospective cohort study by Simon et al (2021, preprint, rated as high quality), detailed above, examined whether vaccination for COVID-19 before or after infection was associated with long COVID (COVID-19 symptoms present between 12 and 20 weeks after COVID-19 diagnosis) in cases who were diagnosed with, or tested positive for (NAAT or antigen test), COVID-19 between 1 January 2020 and 31 May 2021 in the US (13).

- Cases who were vaccinated 0 to 4 weeks after diagnosis were much less likely to have any symptoms of long COVID between 12 and 20 weeks after diagnosis than cases who were unvaccinated up to 12 weeks after their diagnosis (OR = 0.38, 95% CI: 0.35 to 0.41, p<0.005), and even less likely to have more than 1 symptom of long COVID (OR = 0.19, 95% CI: 0.16 to 0.22, p<0.005)
- Cases who were vaccinated 4 to 8 weeks after diagnosis were less likely to have any symptoms of long COVID between 12 and 20 weeks after diagnosis than cases who were unvaccinated up to 12 weeks after their diagnosis (OR = 0.54, 95% CI: 0.51 to 0.57, p<0.005), and much less likely to have more than 1 symptom of long COVID (OR = 0.32, 95% CI: 0.29 to 0.35, p<0.005)
- Cases who were vaccinated 8 to 12 weeks after diagnosis were less likely to have any symptoms of long COVID between 12 and 20 weeks after diagnosis
than cases who were unvaccinated up to 12 weeks after their diagnosis (OR = 0.75, 95% CI: 0.71 to 0.78, p<0.005), and much less likely to have more than 1 symptom of long COVID (OR = 0.46, 95% CI: 0.43 to 0.49, p<0.005).

A prospective cohort (ComPaRe long COVID cohort) study by Tran et al (2021, preprint, rated as high quality) examined the effect of vaccination on long COVID symptoms in adults (≥18 years old) who had a COVID-19 infection (confirmed or suspected) and subsequent long COVID symptoms (symptoms persisting >3 weeks past initial infection) between November 2020 and May 2021 in France (15). Participants (n=910, median age of 47 years, 80.5% female, median of 10.7 months of symptoms) were contacted every 60 days and asked about 53 COVID-19 symptoms (to form a COVID ST score, from 0 to 53, representing the number of different symptoms), and every 45 days and asked about vaccination status. Vaccinated (n=455) and unvaccinated (n=455) participants were matched on sex, age, education, comorbidities, confirmed COVID-19 infection, hospitalisation for COVID-19, time from COVID-19 infection and COVID-19 symptoms.

- Long COVID symptoms were less severe in vaccinated compared with unvaccinated participants 120 days after recruitment (mean difference in COVID ST score = -1.8, 95% CI: -2.5 to -1.0), and more vaccinated than unvaccinated participants had remission of all long COVID symptoms (16.6% versus 7.5%, HR = 1.97, 95% CI: 1.23 to 3.15)
- The impact of long COVID on the lives of vaccinated participants was also less than unvaccinated participants (mean difference in COVID impact score = -3.3, 95% CI: -6.2 to -0.5), and fewer vaccinated participants found their symptoms unacceptable (38.9% versus 46.4%, risk difference = -7.5%, 95% CI: -14.4% to -0.5%)

An online survey conducted by Wanga et al (2021, rated as medium quality) compared long-term symptom changes after receiving a COVID-19 vaccination in adults with and without a previous COVID-19 infection in the US (14). The survey was completed in April 2021 (n=100 COVID-19 cases, n=285 adults who had always received a negative COVID-19 test result), and long-term symptoms were defined as symptoms lasting longer than 4 weeks after a positive test for COVID-19 cases, and symptoms lasting longer than 4 weeks after they first started for adults who never had COVID-19. The analysis accounted for sex, age, region, race and ethnicity and education. Long-term symptoms included change in mood, change in smell or taste, chest pain or pressure, cough, diarrhea, difficulty thinking clearly, concentrating, forgetfulness, memory loss or “brain fog”, fatigue, tired, or weakness, fever or chills, hair loss, headache, joint or muscle pain, nausea or vomiting, palpitations (heart racing or pounding), post-exertional malaise (worsening of symptoms after even minor physical, mental, or emotional exertion), problems sleeping, shortness of breath or breathlessness, sore throat, stomach pain, or other symptoms.

- COVID-19 cases were more likely to report that the vaccine improved their long-term symptoms than adults who never tested positive for COVID-19 (28.7% versus 15.7%, p=0.023)
- However COVID-19 cases were also more likely to report that their symptoms worsened following the vaccination (although this was not statistically significant,
16.1% versus 11.2%, p=0.27), and that their symptoms were gone before receiving the vaccine (28.4% versus 13.1%, p=0.007)

- Fewer COVID-19 cases reported that the vaccine did not affect their symptoms at all (26.4% versus 59.2%)

**Research in progress**

Four additional studies were identified that are still in progress:

- An NIHR funded study by Prieto-Alhambra et al will examine the effect of different COVID-19 vaccines on long COVID in the UK (23).
- A study by Massey et al (Project COVID Recovery: Vaccination Study) will measure the changes in participants’ moderate to severe PASC symptoms at 6, 12 and 15 weeks after vaccination in the US (24).
- A study by Premkumar et al (EvaLongCovid, NCT05107271) will measure long haul COVID-19 related symptoms in adults with chronic liver disease in India (25).
- A randomised controlled trial by the Área de Ensayos Clínicos (EUCTR2021-003331-28-ES) will randomise adults with COVID symptoms persisting 3 weeks after the acute phase of COVID-19 in Spain to either the Pfizer vaccine or placebo, and measure the change in frequency and intensity of symptoms (26).
Research Limitations

Most studies included in this report compared people with COVID-19 or long COVID who were vaccinated with people who were not vaccinated. As there are many differences between people who are and are not vaccinated, there is a risk in all these studies that factors other than vaccination status may have influenced the results (in any direction), although some studies accounted for this well (8, 11-13, 15). The selection of participants may also have affected the results, especially for the online surveys, as people may have chosen to take part because they had either good or poor experiences with long COVID and vaccination, and for studies that recruited from hospitals, where participants may have had more severe disease or comorbidities. In studies where participants report on symptom change shortly after vaccination, the results may reflect short-term reactions to vaccination in addition to changes in long-term symptoms.

Long COVID was defined inconsistently across studies, both in terms of the symptoms that would comprise long COVID, but also the time frame in which the symptoms needed to be present (long COVID, or post-COVID syndrome, in the UK is typically defined as COVID-19 symptoms beyond 12 weeks). This is particularly true of the studies where long COVID was defined as a composite of several different symptoms. This increased the heterogeneity between studies, though as the results were still relatively consistent, this may also be considered a strength. The studies were also conducted at different points in the pandemic and in different countries, and notably no studies accounted for, or reported on, the COVID-19 variant in their analyses.

The studies where vaccination occurred before infection only included people who were infected with COVID-19, meaning no effect of vaccination on preventing COVID-19 infection in the first place was included in the results. As such, the total effect of vaccination on prevention of long COVID will have been underestimated.

Review limitations

This summary was produced at pace over several days so formal data extraction was not conducted. Most of the work was completed by one reviewer, although all narrative summaries were checked by a second reviewer.
Conclusion

There is evidence that vaccinated people who are subsequently infected with COVID-19 are less likely to report symptoms of long COVID than unvaccinated people, in the short term (4 weeks after infection), medium term (12 to 20 weeks after infection) and long term (6 months after infection). This is in addition to any benefit of vaccination in preventing COVID-19 infection (5). There is also evidence that unvaccinated people with long COVID who were subsequently vaccinated had, on average, reduced long COVID symptoms (though some people reported worsened symptoms after vaccination). Additionally, there was evidence that unvaccinated people with long COVID who were subsequently vaccinated reported fewer long COVID symptoms than those who remained unvaccinated. However, there is a risk of bias across all studies due to differences in people who were vaccinated and unvaccinated, the measurement of outcomes, and in the selection of participants.

Acknowledgement

We would like to thank colleagues within the Public Health Advice, Guidance and Expertise function who either reviewed or input into aspects of the review, particularly Graham Burns, Andrew Lee, Jamie Lopez Bernal, and Allison Streetly.

Disclaimer

UKHSA’s rapid reviews aim to provide the best available evidence to decision makers in a timely and accessible way, based on published peer-reviewed scientific papers, unpublished reports and papers on preprint servers. Please note that the reviews: i) use accelerated methods and may not be representative of the whole body of evidence publicly available; ii) have undergone an internal, but not independent, peer review; and iii) are only valid as of the date stated on the review.

In the event that this review is shared externally, please note additionally, to the greatest extent possible under any applicable law, that UKHSA accepts no liability for any claim, loss or damage arising out of, or connected with the use of, this review by the recipient and/or any third party including that arising or resulting from any reliance placed on, or any conclusions drawn from, the review.
References

15. Tran V-T, Perrodeau E, Saldanha J, Pane I, Ravaud P. Efficacy of COVID-19 Vaccination on the Symptoms of Patients With Long COVID: A Target Trial Emulation Using Data From the


<table>
<thead>
<tr>
<th>Study</th>
<th>Country, date</th>
<th>Population</th>
<th>Sample size</th>
<th>Vaccine(s)</th>
<th>Long COVID definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antonelli</td>
<td>UK, Dec 2020 to Jul 2021</td>
<td>Adults with positive COVID-19 test (RT-PCR or LFD) reported to the ZOE app</td>
<td>n=4,740 (2,370 unvaccinated, 2,370 fully vaccinated)</td>
<td>NR</td>
<td>Long duration symptoms of COVID-19 (≥28 days)</td>
</tr>
<tr>
<td>Al-Aly</td>
<td>US, Feb to Aug 2021</td>
<td>Adults with positive COVID-19 test recorded in the US VHA database</td>
<td>n=64,571 (48,536 unvaccinated, 16,035 vaccinated)</td>
<td>NR</td>
<td>Post-acute sequelae of COVID-19 (symptoms of COVID-19 at 6 months, including cardiovascular disorders, coagulation, fatigue, gastrointestinal disorders, kidney disorders, mental health disorders, metabolic disorders, musculoskeletal disorders, neurologic disorders, and pulmonary disorders)</td>
</tr>
<tr>
<td>Arjun</td>
<td>India, Apr to Sep 2021</td>
<td>Adults with positive COVID-19 test (RT-PCR) from a hospital</td>
<td>n=487 (122 unvaccinated, 287 vaccinated [doses NR])</td>
<td>Covaxin (majority)</td>
<td>Self-reported long COVID symptoms (including fatigue, cough, loss of taste and smell and cognitive dysfunction 4 weeks from the date of diagnosis)</td>
</tr>
<tr>
<td>Herman</td>
<td>Indonesia, up to Dec 2021</td>
<td>People (age NR) with positive COVID-19 test (RT-PCR, NAAT or LFD) from across the country</td>
<td>n=442 (221 unvaccinated, 221 fully vaccinated)</td>
<td>NR</td>
<td>Olfactory dysfunction (anosmia or hyposmia) 2 and 4 weeks after the end of infection</td>
</tr>
<tr>
<td>Kuodi</td>
<td>Israel, Mar to Jun 2021 (COVID-19 infection), Jul to Nov 2021 (survey completion)</td>
<td>Adults with positive COVID-19 test from a hospital</td>
<td>n=951 (317 unvaccinated, 294 fully vaccinated)</td>
<td>NR</td>
<td>Long-term physical, mental, and psychosocial consequences of COVID-19, including fatigue, headache, weakness in arms and legs, persistent muscle pain, loss of concentration, hair loss, sleeping problems, dizziness, persistent cough, shortness of breath, and feeling fully recovered from COVID-19</td>
</tr>
<tr>
<td>Senjam</td>
<td>India, Jan to Apr 2021</td>
<td>Adults with positive COVID-19 test (RT-PCR or NAAT) from a hospital</td>
<td>n=773 (407 unvaccinated, 193 fully vaccinated)</td>
<td>NR</td>
<td>Long COVID symptoms present between 4 and 12 weeks (short-term) or beyond 12 weeks (long-term), including fatigue, pain in the joints and muscle, hair loss, headache, cough, breathlessness, sleep disorders, sore throat and decrease of smell and taste</td>
</tr>
<tr>
<td>Simon</td>
<td>US, Jan 2020 to May 2021</td>
<td>People (any age) with positive COVID-19 test (NAAT or antigen test) from across the country</td>
<td>n=240,648 (220,460 unvaccinated, 17,796 fully vaccinated by 12 weeks after infection)</td>
<td>Pfizer, AstraZeneca, Moderna (all approved for use)</td>
<td>COVID-19 symptoms present between 12 and 20 weeks after COVID-19 diagnosis, including chest pain, palpitations, altered mental state, anorexia, chills, fatigue, fever, malaise, loss of sense of smell, loss of sense of taste, nasal congestion, sore throat, abdominal pain, diarrhoea, digestive changes, nausea, vomiting, arthralgia, muscle weakness, general weakness, myalgia, headache, cough and dyspnoea</td>
</tr>
<tr>
<td>Taquet</td>
<td>US, Jan to Aug 2021</td>
<td>People (age NR) with confirmed COVID-19 or positive COVID-19 test (RT-PCR) from across the country</td>
<td>n=18,958 (9479 unvaccinated, 2,996 partially vaccinated, 6,957 fully vaccinated)</td>
<td>Pfizer (65%), Moderna (9%), Janssen (1.6%), unspecified (24%)</td>
<td>Any of the following diagnosed symptoms in the 6 months after infection: abdominal symptoms, abnormal bleeding, anxiety/depression, chest/throat pain, cognitive symptoms, fatigue, headache, myalgia and other pain, and death</td>
</tr>
<tr>
<td>Study</td>
<td>Country, date</td>
<td>Population</td>
<td>Sample size</td>
<td>Vaccine(s)</td>
<td>Long COVID definition</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-----------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Arnold (7)</td>
<td>UK, Apr to May 2020 (COVID-19 hospitalisation), Jan to Feb 2021 (vaccination)</td>
<td>Adults previously hospitalised with COVID-19</td>
<td>n=66 (22 unvaccinated, 44 partially vaccinated)</td>
<td>Pfizer, AstraZeneca</td>
<td>Persistent symptoms of long COVID, including fatigue, breathlessness, insomnia, ear, nose and throat symptoms, brain fog, muscle aches, anosmia, joint pain, cough, headache, palpitations, chest pain, diarrhoea, abdominal pain and nausea</td>
</tr>
<tr>
<td>Ayoubkhani (8)</td>
<td>UK, Feb to Sept 2021</td>
<td>Adults with confirmed COVID-19 (RT-PCR) and long COVID symptoms (self-classified)</td>
<td>n=28,356 (all partially vaccinated by study end, 23,753 fully vaccinated by study end)</td>
<td>mRNA vaccine (45%), adenovirus vector vaccine (55%)</td>
<td>Long duration symptoms of COVID-19 (≥28 days) that could not be explained by another condition, including fever, headache, muscle ache, weakness or tiredness, nausea or vomiting, abdominal pain, diarrhoea, loss of appetite, loss of taste, loss of smell, sore throat, cough, shortness of breath, chest pain, palpitations, vertigo or dizziness, worry or anxiety, low mood or not enjoying anything, trouble sleeping, memory loss or confusion, or difficulty concentrating</td>
</tr>
<tr>
<td>Gaber (10)</td>
<td>UK, Dec 2020 to Jan 2021</td>
<td>Healthcare workers with long COVID</td>
<td>n=77 (10 unvaccinated, 67 partially vaccinated)</td>
<td>Pfizer (100%)</td>
<td>Long COVID symptoms, including fatigue, shortness of breath and anxiety</td>
</tr>
<tr>
<td>Strain (21)</td>
<td>UK, Mar to Apr 2021</td>
<td>Adults with confirmed (RT-PCR/serology) or suspected COVID-19, and long COVID symptoms</td>
<td>n=812 (698 partially vaccinated, 114 fully vaccinated)</td>
<td>AstraZeneca (50%), Pfizer (40%), Moderna (8.6%)</td>
<td>Current or recent symptoms of long COVID-19, including fatigue, brain fog, myalgia, shortness of breath, insomnia, chest pain or palpsitations, gastrointestinal symptoms, anosmia, autonomic dysfunction, postural orthostatic tachycardia syndrome, persistent cough, fever, rash (including COVID toes) and vascular complications.</td>
</tr>
<tr>
<td>Scherlinger (20)</td>
<td>France, Aug 2021</td>
<td>Adults with confirmed (RT-PCR/serology) or suspected COVID-19, and long COVID symptoms</td>
<td>n=567 (170 unvaccinated, 255 partially vaccinated, 142 fully vaccinated)</td>
<td>Pfizer (78.1%), Moderna (16.4%), AstraZeneca (4.3%), mRNA/vector vaccine combination (0.5%)</td>
<td>Post-acute sequelae of COVID-19 symptoms (≥2 days) and no alternative diagnosis, with symptoms including fever or chills, fatigue, brain fog, headaches, changing mood or impact on morale, sleeping issues, costal pain, dyspnoea, cough, palpitations, muscle aches, joint pain, paraesthesia or tingling, anosmia or ageusia, diarrhoea or vomiting, spontaneous bruises, and pruritus</td>
</tr>
<tr>
<td>Tran (15)</td>
<td>France, Nov 2020 to May 2021</td>
<td>Adults with confirmed or suspected COVID-19, and at least 1 long COVID symptom</td>
<td>n=910 (455 unvaccinated, 455 vaccinated)</td>
<td>Pfizer (78.9%), AstraZeneca (10.5%), Moderna (10.3%), Janssen (0.2%)</td>
<td>Long duration symptoms of COVID-19 (≥3 weeks), including 53 symptoms</td>
</tr>
<tr>
<td>Wanga (14)</td>
<td>US, Jan 2020 to Apr 2021 (symptoms), Apr 2021 (survey)</td>
<td>Adults tested for COVID-19 (whether positive or negative)</td>
<td>n=385 ≥1 vaccine dose (100 COVID-19 cases, 285 all prior COVID-19 tests negative)</td>
<td>NR</td>
<td>Long duration symptoms of COVID-19 (≥28 days), including change in mood, change in smell or taste, chest pain or pressure, cough, diarrhoea, difficulty thinking clearly, concentrating, forgetfulness, memory loss or “brain fog”, fatigue, tired, or weakness, fever or chills, hair loss, headache, joint or muscle pain, nausea or vomiting, palpitations (heart racing or pounding), post-exertional malaise (worsening of symptoms after even minor physical, mental, or emotional exertion), problems sleeping, shortness of breath or breathlessness, sore throat, stomach pain, or other symptoms</td>
</tr>
</tbody>
</table>

Acronyms: LFD = lateral flow device, NAAT = nucleic acid amplification test, NR = not reported, RT-PCR = reverse transcriptase polymerase chain reaction  
Fully vaccinated = 2 doses of a 2 dose vaccine or 1 dose of a single dose vaccine; partially vaccinated = 1 dose of a 2 dose vaccine; unvaccinated = no vaccine received  
*Simon et al looked at vaccination before and after infection
Appendix A – Methods

This report employed a rapid review approach to address the review question:

Are vaccinations against COVID-19, before or after infection, effective against long COVID?

Our rapid review approach follows streamlined systematic methodologies (27). In particular, title and abstract screening was completed by 1 reviewer, and full text screening and summarisation of the studies were performed by one reviewer and checked by another. Risk of bias was assessed by 1 reviewer, using the quality criteria checklist (QCC) tool (28).

We searched a number of specialist COVID-19 review repositories and ran a broad search using Medline, Embase, NLM COVID portfolio (for preprints), WHO COVID Database and Google. Searches were conducted for papers published between 1 January 2020 and 12 January 2022. Search terms covered key aspects of the review question. The search strategy for Ovid Medline is presented in Box A.1.

Box A.1. Search strategy Ovid Medline

<table>
<thead>
<tr>
<th></th>
<th>Search Term</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>vaccinat*.tw,kw.</td>
<td>175921</td>
</tr>
<tr>
<td>2</td>
<td>vaccine*.tw,kw.</td>
<td>271324</td>
</tr>
<tr>
<td>3</td>
<td>previously-vaccin*.tw,kw.</td>
<td>1021</td>
</tr>
<tr>
<td>4</td>
<td>post-vaccin*.tw,kw.</td>
<td>5742</td>
</tr>
<tr>
<td>5</td>
<td>early-vaccin*.tw,kw.</td>
<td>423</td>
</tr>
<tr>
<td>6</td>
<td>late-vaccin*.tw,kw.</td>
<td>84</td>
</tr>
<tr>
<td>7</td>
<td>moderna.tw,kw.</td>
<td>618</td>
</tr>
<tr>
<td>8</td>
<td>mRNA-1273.tw,kw.</td>
<td>451</td>
</tr>
<tr>
<td>9</td>
<td>pfizer.tw,kw.</td>
<td>4091</td>
</tr>
<tr>
<td>10</td>
<td>BNT162b2.tw,kw.</td>
<td>1349</td>
</tr>
<tr>
<td>11</td>
<td>JNJ-78436735.tw,kw.</td>
<td>5</td>
</tr>
<tr>
<td>12</td>
<td>“Johnson &amp; Johnson”*.tw,kw.</td>
<td>943</td>
</tr>
<tr>
<td>13</td>
<td>Astrazeneca.tw,kw.</td>
<td>1690</td>
</tr>
<tr>
<td>14</td>
<td>Oxford-Astrazeneca.tw,kw.</td>
<td>172</td>
</tr>
<tr>
<td>15</td>
<td>AZD 1222.tw,kw.</td>
<td>3</td>
</tr>
<tr>
<td>16</td>
<td>AZD1222.tw,kw.</td>
<td>165</td>
</tr>
<tr>
<td>17</td>
<td>BNT 162b2.tw,kw.</td>
<td>14</td>
</tr>
<tr>
<td>18</td>
<td>ChAdOx1.tw,kw.</td>
<td>564</td>
</tr>
<tr>
<td>19</td>
<td>Novavax.tw,kw.</td>
<td>38</td>
</tr>
<tr>
<td>20</td>
<td>NVX-CoV2373.tw,kw.</td>
<td>24</td>
</tr>
<tr>
<td>21</td>
<td>Sputnik V.tw,kw.</td>
<td>57</td>
</tr>
<tr>
<td>22</td>
<td>Ad26.tw,kw.</td>
<td>83</td>
</tr>
<tr>
<td>23</td>
<td>&quot;Ad26.COV2&quot;.tw,kw.</td>
<td>15</td>
</tr>
<tr>
<td>24</td>
<td>Ad5.tw,kw.</td>
<td>2669</td>
</tr>
<tr>
<td>25</td>
<td>Janssen.tw,kw.</td>
<td>1173</td>
</tr>
</tbody>
</table>
26 Sinovac.tw.kw. (77)
27 sinopharm.tw.kw. (52)
28 covaxin.tw.kw. (43)
29 exp Vaccination/ (95675)
30 COVID-19 Vaccines/ (7849)
31 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 (372560)
32 transmiss*.tw.kw. (426659)
33 transmit*.tw.kw. (180675)
34 viral load*.tw.kw. (36428)
35 viral burden.tw.kw. (1064)
36 ((severity or severe) adj2 (disease or illness)).tw.kw. (117155)
37 exp Coronavirus Infections/ (77194)
38 32 or 33 or 34 or 35 or 36 or 37 or 38 (769168)
39 exp coronavirus/ (116957)
40 exp Coronavirus Infections/ (142168)
41 COVID-19/ (131372)
42 ((corona* or corono*) adj1 (virus* or viral* or virinae*)).ti,ab,kw. (4131)
43 coronavirus* or coronovirus* or coronavirinae* or CoV or HCoV*.ti,ab,kw. (121211)
44 covid*.nm. (7853)
45 (2019-nCoV or 2019nCoV or nCoV2019 or nCoV-2019 or COVID-19 or COVID19 or CORVID-19 or CORVID19 or WN-CoV or WNCoV or HCoV-19 or HCoV19 or 2019 novel* or Ncov or n-cov or SARS-CoV-2 or SARS-CoV2 or SARS-CoV2 or SARS-CoV19 or SARS-Cov19 or SARS-Cov-19 or Ncov or Ncorna* or Ncorono* or NcovWuhan* or NcovHubei* or NcovChina* or NcovaChinese* or SARS2 or SARS-2 or SARS-coronavirus2 or SARS-coronavirus-2 or SARS-coronavirus 2 or SARS coronavirus2 or SARS-coronavirus2 or SARS-coronavirus-2 or SARS-coronavirus 2 or SARS coronavirus2).ti,ab,kw. (204081)
46 respiratory* adj2 (symptom* or disease* or illness* or condition*) adj10 (Wuhan* or Hubei* or China* or Chinese* or Huanan*).ti,ab,kw. (700)
47 ((seafood market* or food market* or pneumonia*) adj10 (Wuhan* or Hubei* or China* or Chinese* or Huanan*).ti,ab,kw. (2159)
48 outbreak* or wildlife* or pandemic* or epidemic* adj1 (Wuhan* or Hubei or China* or Chinese* or Huanan*).ti,ab,kw. (465)
49 or/40-49 (238986)
50 31 and 39 and 50 (4420)
51 COVID-19/tm [Transmission] (4367)
52 COVID-19 Vaccines/ (7849)
53 31 and 52 (520)
54 COVID-19 vi/tm [Virology] (8817)
55 31 and 56 (1561)
56 51 or 53 or 55 or 57 (5712)
Article eligibility criteria are summarised in Table A.1.

**Table A.1. Inclusion and exclusion criteria**

<table>
<thead>
<tr>
<th>Included</th>
<th>Excluded</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Population</strong></td>
<td>All populations</td>
</tr>
<tr>
<td><strong>Settings</strong></td>
<td>All community settings, including households</td>
</tr>
<tr>
<td><strong>Context</strong></td>
<td>COVID-19 pandemic</td>
</tr>
<tr>
<td><strong>Intervention / exposure</strong></td>
<td>Partial or full vaccination against COVID-19; any COVID-19 specific vaccination; vaccination before or after COVID-19 infection</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>Incidence or prevalence of long COVID using any definition given by individual studies, including symptoms of COVID-19 &gt;28 days after the initial infection</td>
</tr>
<tr>
<td><strong>Language</strong></td>
<td>English</td>
</tr>
</tbody>
</table>
Title and abstract screening was completed by 1 reviewer. Full text screening and study summaries were completed by one reviewer and checked by a second. Only results directly relevant to the review questions were summarised.

Studies were assessed by 1 reviewer, using the QCC for primary research (28). This risk of bias tool can be applied to most study designs (observational and interventional) and is therefore suitable for rapid reviews of mixed type of evidence. It is composed of 10 validity questions based on the criteria and domains identified by the Agency for Healthcare Research and Quality to assess the methodological quality of a study (that is, the extent to which a study has minimised selection, measurement and confounding biases) (29). In the QCC tool, 4 questions are considered critical (on selection bias, group comparability/confounding, interventions/exposure and outcome). A study will be rated as high quality if the answers to the 4 critical questions are ‘yes’ (and at least one additional ‘yes’). The study will be rated as low quality if 2 or more of the critical questions are answered ‘no’ and/or if ≥50% of the remaining questions are answered ‘no’. Otherwise, the study will be rated as medium quality. Judgments were made on case by case for questions answered as ‘unclear’. To note that we report these ratings as ‘quality’ ratings for consistency with the name of the tool, although here quality needs to be understood as ‘methodological quality’ as part of a risk of bias assessment.

The PRISMA diagram showing the flow of citations is provided in Figure A.1.
Figure A.1: PRISMA flowchart

**Identification of studies via databases and registers**

- Records identified from databases: 1,123
  - Ovid Medline (n=141)
  - Ovid Embase (n=132)
  - Cochrane COVID Registry (n=405)
  - medRxiv (n=71)
  - SSRN (n=18)
  - I.Loye (n=218)
  - WHO COVID database (n=138)

**Identification of studies via other methods**

- Records identified from:
  - Expert consultation (n=1)

**Identification of studies via databases and registers**

- Records screened (n=729)

**Screening**

- Papers sought for retrieval (n=20)

**Included**

- Papers assessed for eligibility (n=20)
  - Reports excluded: 6
    - Wrong outcome (n=5)
    - Withdrawn from preprint server (n=1)

- Papers included in the review (n=15)

- Records removed before screening:
  - Duplicate records removed (n=394)
  - Records marked as ineligible by automation tools (n=0)
  - Records removed for other reasons (n=0)
About the UK Health Security Agency

The UK Health Security Agency is an executive agency, sponsored by the Department of Health and Social Care. www.ukhsa.gov.uk

© Crown copyright 2022

Prepared by: Sean Harrison, Bethany Walters, Zalaya Simmons, Michael Cook and Rachel Clark

For queries relating to this document, please contact: Covid19Evidence@phe.gov.uk

For other published rapid COVID-19 evidence reviews, please visit https://ukhsalibrary.koha-pfts.co.uk/covid19rapidreviews/

Published: February 2022

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.